PinPoint Data Science's AI blood test is moving from trial evidence towards NHS use after AI News cited a 16,481-patient Yorkshire study of urgent suspected-cancer referrals.

The first hospital deployments are aimed at women referred with possible womb cancer, but Cancer Research UK said more research is still needed to judge the benefit for patients and the NHS.

PinPoint AI Blood Test Enters NHS Cancer Referrals

AI News said Mid Yorkshire NHS Teaching Trust and Leeds Teaching Hospitals NHS Trust are preparing to use the PinPoint test.

The former is expected to apply it across six gynaecological or upper gastrointestinal cancer routes, while the Leeds trust is using it for gynaecological cancer.

PinPoint Data Science, based in Leeds, built the tool to use machine learning on blood-marker data.

AI News said the test separates patients into low, elevated and high-risk groups after reviewing around 30 markers, and PinPoint said clinicians receive a risk score that can sit inside existing cancer referral workflows.

AI News attributed national demand figures to The Guardian.

The Guardian figures cited by AI News put annual GP referrals after heavy bleeding at around 90,000 postmenopausal women in England, with about 10,000 womb cancer diagnoses each year and around 2,700 deaths from the disease.

Yorkshire Trial Covered 16,481 Urgent Referrals

The reported evidence base is a Yorkshire trial covering 16,481 people sent through urgent suspected-cancer pathways.

AI News said the group included women whose symptoms raised concern about womb or other gynaecological cancers.

AI News cited the trial results as finding cancer in about one in 10 women referred because of heavy bleeding.

PinPoint said its system marked 99.1% of cancers as elevated or high risk and produced a 99.8% negative predictive value for women placed in the lowest-risk group.

PinPoint said the test costs around £30.

The company also described the product as a multi-cancer test, with prior use in pathways covering gynaecological cancers, lung cancer, upper and lower gastrointestinal cancers, and head and neck cancer.

NHS Diagnostic Route Still Needs Outcome Evidence

AI News said the current route for suspected reproductive-system cancers commonly starts with a pelvic examination and a transvaginal ultrasound scan, with biopsy or hysteroscopy possible when suspicion remains.

PinPoint's stated aim is to identify very low-risk patients before those more invasive checks are needed.

PinPoint said the blood test could remove the need for a transvaginal ultrasound scan for about one in five referred women in England, equivalent to around 18,000 patients a year.

AI News identified Professor Sean Duffy as PinPoint's chief medical officer and a former NHS England national cancer director; he said the clinical value is in ruling out patients at very low risk.

AI News placed the PinPoint rollout alongside other NHS uses of AI, including MEMORI at Kent and Canterbury Hospital, an NHS App triage tool and AI-supported chest X-ray tools for suspected lung cancer.

NHS England said the triage tool should be used by more than 200,000 patients within 12 months, with full NHS App availability expected by April 2028, while the government has committed £20 million to bring AI chest X-ray tools across NHS trusts in England by 2029.

Cancer Research UK called the PinPoint test promising while saying more evidence is needed on its benefits.

AI News did not include final national rollout dates, patient-outcome data, regulatory clearance details or measured NHS capacity savings from the womb cancer test.